USA flag logo/image

An Official Website of the United States Government

A Rapid Lateral Flow Test for TB in Nonhuman Primates

Award Information

Agency:
Department of Health and Human Services 		Branch:
N/A 		Award ID:
54240 		Program Year/Program:
2001 / SBIR
Agency Tracking Number:
1R43AI050271-01 		Solicitation Year:
N/A 		Solicitation Topic Code:
N/A 		Solicitation Number:
N/A
Small Business Information
SEQUELLA, INC.
9610 MEDICAL CENTER DR, STE 200 ROCKVILLE, MD 20850-6332
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2001
Title: A Rapid Lateral Flow Test for TB in Nonhuman Primates
Agency: HHS
Contract: N/A
Award Amount: $162,215.00
 

Abstract:

DESCRIPTION (provided by applicant): The goal of the research is to develop a rapid, lateral flow, antibody-based diagnostic test for tuberculosis (TB) in nonhuman primates. The unreliability of the present TB skin test underlies the frequent devastating outbreaks of TB among primates in zoos, quarantine facilities, and in colonies maintained for use in medical research. False positive responses to the present skin test result in the needless destruction of many healthy animals each year. An improved method of diagnosing TB in nonhuman primates is urgently needed. The research proposed is a feasibility study of a new approach to the diagnosis of simian TB, based upon the occurrence of antibodies to TB antigens during the course of the disease. Two U.S. biotechnology companies will pool their resources, which include a bank of stored serum samples and a valuable collection of recombinant proteins and peptides from Mycobacterium tuberculosis. The Phase I research would assess the feasibility of developing a rapid lateral flow diagnostic that would require only a drop of blood and would provide accurate results within minutes. The proposed assay is based upon an innovative proprietary technology. Quantitative criteria for establishing the feasibility of this novel approach are stated, and require demonstrating high sensitivity and specificity of a prototype assay during Phase I. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

Principal Investigator:

Carol A. Nacy

Business Contact:


3017627776
LEOEINCK@SEQUELLA.COM
Small Business Information at Submission:

SEQUELLA, INC.
9610 MEDICAL CENTER DR, STE 200 ROCKVILLE, MD 20850

EIN/Tax ID: 522044703
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No